Please assess the completion status of the following clinical trial:

Trial Title: Quetiapine Extended Release (XR) for the Treatment of Menopausal Depression

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* women 40 to 60 years~* diagnosis of MDD~* perimenopausal or postmenopausal~Exclusion Criteria:~* using HRT~* using psychotropic medications~* other DSM-IV axis I diagnoses other than MDD

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): Use of quetiapine, flexible dose (150-300 mg/day) for 8 weeks, following a 2-week placebo lead-in phase

Based on this trial design, predict the completion outcome and termination type (if applicable).